74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Talphera Inc.
Closed
0.72 -4
Overview
Share price change
24h
Min
0.72
Max
0.75
Income | 664K -3.8M |
|---|---|
Profit margin | -443,600 |
Employees | 13 |
Recommendations | Buy |
|---|---|
12 Months Forecast | +316.67% upside |
Next Earnings | 13 May 2026 |
|---|
Market Cap | -1.6M 32M |
|---|---|
Previous open | 4.72 |
Previous close | 0.72 |
Talphera Inc. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Talphera Inc. Forecast
Price Target
By TipRanks
316.67% upside
12 Months Forecast
Average 3.25 USD 316.67%
High 3.5 USD
Low 3 USD
Based on 2 Wall Street analysts offering 12 month price targets forTalphera Inc. - Dist in the last 3 months.
Financials
Selling and administration expenses
Pre-tax profit
Sales
Interest expense on debt
Operating profit
$
About Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Live chat